Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders
Reviewed by Jonathan Chan

Medical records of 15 paediatric patients (onset before age of 16) affected by refractory non-infectious uveitis (NIU) and treated by tocilizumab (TCZ) were reviewed. Data were extracted from the international AIDA Network for uveitis registry and Behcet’s disease registries. They were treated with TCZ, either intravenously (8–12mg/kg every 4 weeks) or subcutaneously (162mg weekly). Bilateral ocular involvement was present in all except one patient. The ocular relapses significantly reduced from a mean of 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid sparing effect was decreased (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes. The authors concluded that multicentre studies with larger sample sizes are required to address the limitations of small sample size, variability in disease management across centres and lack of randomisation in this report.

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders.
Sota J, Breda L, Paroli MP, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2025;109(10):1151–4.